CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) — hC Bioscience, Inc., a biotech firm creating first-in-class tRNA-based therapeutics concentrating on protein dysfunction in genetically outlined illnesses and most cancers, right now introduced it has expanded its govt and analysis & growth groups with the additions of Yosef Landesman, Ph.D., as chief scientific officer and Gautam Goel, Ph.D., as chief knowledge science officer.
“I am excited to announce the continued expansion of our team as we build upon our three pillars of expertise: translation and tRNA biology, computation and delivery,” said Leslie Williams, co-founder, president and chief govt officer of hC Bioscience. “The appointments of Drs. Landesman and Goel build on the addition of Dr. David Altreuter, who previously joined hC Bioscience as chief technology officer. Under their leadership, we continue to add members to our R&D team with expertise in tRNA biology, computational and formulation. With the exceptional talent we have attracted, we believe we are well-positioned to advance our complementary tRNA based therapeutic platforms towards multiple key milestones.”
Dr. Landesman brings 20 years of expertise in drug discovery, growth and regulatory approval within the biotech and pharmaceutical industries. Prior to becoming a member of hC Bioscience, Dr. Landesman served as senior vice chairman of analysis and translational drugs at Karyopharm Therapeutics. From 2011 by means of 2022, his management was essential to advancing preclinical and scientific analysis, preclinical DMPK, translational drugs, bioinformatics and Karyopharm’s Expanded Access Program. Prior to Karyopharm, Dr. Landesman labored at Alnylam Pharmaceuticals the place he performed a essential function in establishing the RNAi Lead Development division and contributed to the event of ONPATTRO® (patisiran). Dr. Landesman earned his doctorate in Molecular Genetics and Virology from the Weizmann Institute of Science, and subsequently accomplished postdoctoral coaching and grew to become school at Harvard Medical School.
Dr. Goel is a frontrunner in translational computational biology and a seasoned skilled with an impactful 20-year observe report in biotech, academia and tech. Dr. Goel most not too long ago constructed and led an inter-disciplinary R&D/consulting observe to implement pipelines for evaluation of multi-omics datasets together with single-cell RNA-seq, CyTOF, proteomics and metabolomics from cross-sectional/longitudinal intervention research. Prior to this place, Dr. Goel spearheaded biomarker analysis and platform growth as director of precision drugs at ImmusanT to speed up scientific growth of antigen-specific Immunotherapies. Dr. Goel skilled as a Research Fellow at Massachusetts General Hospital and The Broad Institute with Dr. Ramnik J. Xavier. He earned his doctorate and MS in Bioengineering from Georgia Institute of Technology, an MS in Computer Science from National Center for Software Technology and a BS in Mechanical Engineering from University of Pune.
Steven Gillis, chairman of hC Bioscience’s board of administrators and managing director of ARCH Ventures, “With the core team in place at hC Bioscience, I believe the company is poised to rapidly translate foundational IP into tRNA based therapies for patients with cancer and life-limiting genetic diseases. We look forward to continuing our support of their work towards transforming how many cancers and genetic diseases are treated.”
About hC Bioscience, Inc.
hC Bioscience is devoted to enhancing the lives of sufferers with the event of first-in-class tRNA-based therapeutics concentrating on protein dysfunction. hC Bioscience’s progressive method to precision protein enhancing has the potential to deal with genetically outlined circumstances which account for 10-15% of all human illness. The lead platform in growth is directed at restoring protein operate in illnesses attributable to nonsense mutations or untimely termination codons (PTCs). A single tRNA remedy has the potential to deal with many illnesses, whatever the gene or location of the mutation.
Media Contact:
Andrew Mielach
(646) 876-5868
[email protected]
